Compugen discovers cancer treatment target
NEW YORK Israeli drug developer Compugen Ltd. said Monday it discovered a potential cancer treatment target using its RNA sequence technology.
Drug discovery platform developer Compugen Ltd. almost quadrupled its revenue to $800,000 for the second quarter of 2010 from $225,000 for the corresponding quarter of 2009 thanks to the recognition of initial fees and research revenues from collaborative ventures.